一次性PE手套(加厚型)

一次性PE手套(加厚型)

规格

  • M
  • 产品详情
  • 产品参数

产品组成:由进口聚乙烯制成
产品特点:
● 按照亚洲人手型,符合人体工学,给手部足够的活动空间,不易破损,真正做到灵巧、舒适、安全。
● 严谨的全检检验方式,保证手套的质量,更大程度减少破损,安全无感染。
● 色泽通透柔和,不刺眼,不影响作业。
● 特制麻面处理具有超强吸附力,能有效防滑,取物确实,在抓取器具时不易滑落。
● 不分左右手,取用方便,容易穿戴。
● 加厚处理,质量远超行业内手套,具有超强拉伸强度,柔韧性好,能有效防止穿戴撕裂。
产品颜色:透明色
使用范围:实验室科研卫生防护
保存方法:避免阳光直射,放置在阴凉干燥处

规 格 性质 质量 包装方式
L/ M/ S 麻面 普通型—1.4g 70只/包
50包/箱
加厚型—1.5g


参数

别名
品牌 光明手套(防护用品)订购
货号 E1042AH
货期
单位
保存条件

一次性PE手套

一次性PE手套

规格

  • M
  • 产品详情
  • 产品参数

产品组成:由进口聚乙烯制成
产品特点:
● 按照亚洲人手型,符合人体工学,给手部足够的活动空间,不易破损,真正做到灵巧、舒适、安全。
● 严谨的全检检验方式,保证手套的质量,更大程度减少破损,安全无感染。
● 色泽通透柔和,不刺眼,不影响作业。
● 特制麻面处理具有超强吸附力,能有效防滑,取物确实,在抓取器具时不易滑落。
● 不分左右手,取用方便,容易穿戴。
● 加厚处理,质量远超行业内手套,具有超强拉伸强度,柔韧性好,能有效防止穿戴撕裂。
产品颜色:透明色
使用范围:实验室科研卫生防护
保存方法:避免阳光直射,放置在阴凉干燥处

规 格 性质 质量 包装方式
L/ M/ S 麻面 普通型—1.4g 70只/包
50包/箱
加厚型—1.5g

参数

别名
品牌 光明手套(防护用品)订购
货号 E1042A
货期 现货
单位
保存条件

Soblidotin(Synonyms: Auristatin PE; TZT-1027)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Soblidotin (Synonyms: Auristatin PE; TZT-1027) 纯度: 99.64%

Soblidotin (Auristatin PE) 是一种新型合成的 Dolastatin 10衍生物,抑制剂微管 (tubulin) 聚合。

Soblidotin(Synonyms: Auristatin PE;  TZT-1027)

Soblidotin Chemical Structure

CAS No. : 149606-27-9

规格 价格 是否有货 数量
1 mg ¥1400 In-stock
5 mg ¥3500 In-stock
10 mg ¥5000 In-stock
25 mg ¥10000 In-stock
50 mg ¥15000 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Soblidotin 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus

生物活性

Soblidotin (Auristatin PE) is a novel synthetic Dolastatin 10 derivative and inhibitor of tubulin polymerization.

IC50 & Target

Tubulin[1]

体外研究
(In Vitro)

Soblidotin (Auristatin PE) is a novel synthetic dolastatin 10 derivative that inhibits tubulin polymerization. Soblidotin (Auristatin PE) exhibits antitumor activity against p-glycoprotein-overexpressing cell lines established from colon cancer H116 and breast cancer-resistant protein-positive cell lines established from lung cancer PC-6, and is more potent than Vincristine, Paclitaxel, and Docetaxel against these cell lines[1]. Soblidotin (Auristatin PE) is a synthetic analog of dolastatin 10 which inhibits the growth of several tumoral cell lines and induces caspase-3-dependent apoptosis. Soblidotin (Auristatin PE) also shows antitumoral activity in Vincristine-, Docetaxel-, and Paclitaxel-resistant tumors, which makes it a potential chemotherapy drug for use in tumors which do not respond to other microtubule inhibitors[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Intravenous injection of Auristatin PE (TZT-1027) has been shown to potently inhibit the growth of P388 leukemic cells and several solid tumors in mice, and to prolong the survival of the animals, and its antitumor efficacy has been shown to be superior or comparable to that of the reference agents Dolastatin 10, Cisplatin, Vincristine, and 5-Fluorouracil. Furthermore, in xenograft models, Auristatin PE reduces intratumoral blood perfusion 1 to >24 h after its administration, thereby producing hemorrhagic necrosis of the tumors[1]. Auristatin PE (Soblidotin) shows antivascular effects in tumoral models overexpressing VEGF and in murine colon tumors, with an increase in vascular permeability, vessel closure, and widespread hemorrhage[2]. Mice bearing subcutaneous HT-29 tumors (200 mm3) are dosed every 7 days with Auristatin PE (0.5 or 1.0 mg/kg) for a total of four cycles. Under such conditions, Auristatin PE (TZT-1027) inhibits the growth of HT-29 xenografts in a dose-dependent manner. Coadministration of Auristatin PE does not interfere with the PD184352-induced suppression of ERK1/2 phosphorylation. Immunostaining for Ki-67 as a marker for proliferating cells confirmed that the number of such cells in tumor sections is decreased greatly at 24 hours after the initial dosing with PD184352 compared with that apparent for vehicle-treated tumors. Auristatin PE treatment alone increases the number of TUNEL-positive cells in HT-29 xenografts by 24 hours in a dose-dependent manner, and this effect is enhanced by coadministration of PD184352[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

701.98

Formula

C39H67N5O6

CAS 号

149606-27-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定,建议您现用现配,即刻使用。

溶解性数据
In Vitro: 

DMSO : 100 mg/mL (142.45 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4245 mL 7.1227 mL 14.2454 mL
5 mM 0.2849 mL 1.4245 mL 2.8491 mL
10 mM 0.1425 mL 0.7123 mL 1.4245 mL

*

请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.56 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.56 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.56 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.56 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Yamamoto N, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci. 2009 Feb;100(2):316-21.

    [2]. Fanale D, et al. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst). 2015;2015:690916.

    [3]. Watanabe K, et al. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. Clin Cancer Res. 2010 Feb 15;16(4):1170-8.

Animal Administration
[3]

Mice[3]
Soblidotin (Auristatin PE) and Vinorelbine are dissolved in 0.05 M sodium lactate buffer (pH 4.5) and in PBS, respectively. Mice are treated every 7 d with PD184352 (200 mg/kg) or vehicle by oral administration (four times per day, every 6 h) and with Auristatin PE (0.25-2.5 mg/kg), Vinorelbine (5-20 mg/kg), or vehicle by i.v. injection (once per day, 1 h after the first PD184352 administration). Tumor volume is measured with digital calipers and calculated according to the following formula: (longest diameter)×(shortest diameter)2/2. Body weight, tumor volume, and toxicities are noted every 2 to 4 d for the duration of the experiment.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Yamamoto N, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci. 2009 Feb;100(2):316-21.

    [2]. Fanale D, et al. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst). 2015;2015:690916.

    [3]. Watanabe K, et al. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. Clin Cancer Res. 2010 Feb 15;16(4):1170-8.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Mifamurtide(Synonyms: 米伐木肽; MTP-PE; L-MTP-PE; CGP 19835)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Mifamurtide (Synonyms: 米伐木肽; MTP-PE; L-MTP-PE; CGP 19835) 纯度: ≥98.0%

Mifamurtide (MTP-PE) 是穆拉基二肽 (MDP) 的类似物,一种非特异性免疫调节剂,通过刺激激活巨噬细胞和单核细胞的免疫应答而发挥作用。Mifamurtide 是一种孤儿药,是 NOD2 的特异性配体,用作胰岛素增敏剂。Mifamurtide 具有用于骨肉瘤研究的潜力。

Mifamurtide(Synonyms: 米伐木肽; MTP-PE;  L-MTP-PE;  CGP 19835)

Mifamurtide Chemical Structure

CAS No. : 83461-56-7

规格 价格 是否有货 数量
1 mg ¥12000 In-stock
5 mg 询价
10 mg 询价

* Please select Quantity before adding items.

Mifamurtide 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus

生物活性

Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide, an orphan drug, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide has the potential for osteosarcoma research[1][2][3].

体外研究
(In Vitro)

Mifamurtide (MTP-PE; 100 µM) induces a reduction of MG63 cells number when co-cultured with macrophages[3].
Mifamurtide (100 µM) increases both the M1 polarization marker iNOS and the M2 polarization marker CD206 mRNAs; both pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines. Mifamurtide increases the iron transporter DMT1 protein[3].
L-mifamurtide (5, 5000 nM; for 48 hours) alone has no direct effect on the proliferation rate of the two osteosarcoma cell lines MOS-J and KHOS in vitro or in vivo[1].
Mifamurtide acts as a nonspecific immunomodulator by activating macrophages and monocytes related to the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-8, IL-12, nitric oxide (NO), prostaglandin E2 (PGE2) and PGD2[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Mifamurtide (MTP-PE; 1 mg/kg; i.v.; twice per week for 4 weeks) causes a trend of diminished spontaneous lung metastasis dissemination[1].
Mifamurtide (50 μg/mouse) improves glucose tolerance during endotoxemia in mice. Mifamurtide (equivalent to 20 μg MDP; 4 times per week for 5 weeks) improves glucose tolerance in HFD-fed mice without altering body mass[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6, BALB/c mice with KHOS osteosarcoma cells[1]
Dosage: 1 mg/kg
Administration: IV; twice per week for 4 weeks
Result: Caused a trend of diminished spontaneous lung metastasis dissemination in xenogeneic (KHOS) and syngeneic (MOS-J) models.

Clinical Trial

分子量

1237.50

Formula

C59H109N6O19P

CAS 号

83461-56-7

中文名称

米伐木肽;米法莫肽

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (80.81 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.8081 mL 4.0404 mL 8.0808 mL
5 mM 0.1616 mL 0.8081 mL 1.6162 mL
10 mM 0.0808 mL 0.4040 mL 0.8081 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.02 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (2.02 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (2.02 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.02 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89.

    [2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.

    [3]. Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3.

    [4]. Francesca Punzo, et al. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget. 2020 Feb 18;11(7):687-698.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务